TS Global Awareness Day

May 15 is #TSGlobalDay, the day on which the international Tuberous Sclerosis Community shares information and their stories about TSC to raise awareness of this condition, which affects an estimated 1 million people worldwide. Here are 15 facts about TSC which give the basics about

A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients with Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures NCT02544763

A double-blind, randomized, placebo-controlled study to investigate the efficacy and safety of Cannabidiol (GWP42003-P, CBD) as add-on therapy in patients with Tuberous Sclerosis Complex who experience inadequately-controlled seizures NCT02544763 How long is the study? Study length: 5 weeks of baseline and 16 weeks of treatment

Landmark decision as everolimus for refractory epilepsy in people with Tuberous Sclerosis Complex is accepted for use by NHS Scotland

  MEDIA RELEASE The Scottish Medicines Consortium (SMC) has announced today [Monday, 11 June] that everolimus will be available on prescription to treat refractory epilepsy in people aged two years and older with Tuberous Sclerosis Complex (TSC) in Scotland.   Maxine Smeaton, Chief Executive of